Category: Healthcare and Pharmaceutical
Publish Date: July 2023
No. of Pages: 260
Format: Pdf
Licensing options
What is Idiopathic Pulmonary Fibrosis?
Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic lung disease marked by the stiffening (fibrosis) of the lungs for unexplained reasons. The term "idiopathic" indicates that the disease's precise cause is unknown.
In IPF, the lung tissue is gradually thickened, rigid, and scarred, impairing the lungs' capacity to expand and contract normally. This fibrosis and the subsequent loss of lung function can result in a variety of symptoms, including a chronic dry cough, shortness of breath, exhaustion, and chest pain. Typically, the symptoms develop and worsen progressively.
Idiopathic Pulmonary Fibrosis Market Overview
The Idiopathic Pulmonary Fibrosis Market is expected to witness an exponential growth rate at CAGR of 12.61% during the period 2024 to 2029. The market is valued at USD 4393.72 Million in 2022 which is expected to reach USD 10638.61 Million in 2029. The global Idiopathic Pulmonary Fibrosis market is expected to grow in the coming years, driven by several factors such as the increasing ageing population, growing smoking population and increasing number of lung diseases.
Pharmaceutical companies are making investments in research and development to identify new IPF treatments. Currently, clinical trials are being conducted on a number of drugs that target different mechanisms implicated in the progression of IPF. Among these are antifibrotic agents, immunomodulatory pharmaceuticals, and innovative therapeutic approaches.
Increasing number of geriatric population.
The prevalence of Idiopathic Pulmonary Fibrosis increases with age, and a significant proportion of those afflicted are elderly. The global geriatric population is growing, primarily due to increased life expectancy and declining fertility rates.
The World Health Organization predicts that the number of people aged 60 and older will more than double by 2050. This demographic shift suggests a larger consumer base for Idiopathic Pulmonary Fibrosis-related goods and services. The aging population has a direct effect on the industry by increasing the demand for effective healthcare and management solutions.
Limited therapeutics and treatment options
The goal of the medications that are currently available for idiopathic pulmonary fibrosis (IPF), such as pirfenidone and nintedanib, is not to cure the condition but rather to cease the disease's progression. Although these treatments have demonstrated some benefit in delaying the deterioration of lung function and the advancement of the disease, they are not a total solution to the problem. This limitation can have a negative effect on patient outcomes and contribute to dissatisfaction, as both patients and physicians seek more effective treatments.
Segment-Wise Insights
Pirfenidone segment accounts for USD 2259.30 Million in 2022
Pirfenidone is an antifibrotic drug that has been licensed for the treatment of idiopathic pulmonary fibrosis (IPF) in a number of countries, including the United States, the European Union, and Japan. Oral medicine targets numerous lung fibrotic pathways.
Pirfenidone may have anti-inflammatory, antioxidant, and antifibrotic actions, but its mechanism is unknown. It inhibits TGF-β and TNF-α, pro-inflammatory and pro-fibrotic substances. Pirfenidone reduces inflammation and fibrosis to delay IPF and preserve lung function.
Regional Insights
According to Azoth Analytics Estimates, Americas accounts for the largest revenue share in 2022. Factors driving the growth of the market include a growing aging population, increasing awareness about lung health, and advancements in screenings and diagnostic technology. Europe Idiopathic Pulmonary Fibrosis Market is the fastest growing market with a positive outlook for the future, driven by factors such as an large smoking population, increasing awareness about Idiopathic Pulmonary Fibrosis, and advancements in development of novel therapeutics.
Competitive Landscape
Global Idiopathic Pulmonary Fibrosis Market is fragmented with top 10 companies accounting for a significant revenue share in the year 2022. Leading companies and brands in the market are executing different strategies and partnerships to strengthen the foothold and increase the competitiveness and product offerings in the market.
F. Hoffmann-La Roche AG, Cipla Ltd., Bristol-Myers Squibb Co., and Boehringer Ingelheim among others are the leading companies in the Global Idiopathic Pulmonary Fibrosis Market.
Leading companies in the Global Idiopathic Pulmonary Fibrosis Market include:
Boehringer Ingelheim
F. Hoffmann-La Roche AG
Cipla Ltd.
Shionogi & Co., Ltd.
Bristol-Myers Squibb Co.
United Therapeutics
FibroGen, Inc.
Pliant Therapeutics
Galecto Inc.
CSL Behring
Strategic Developments in the Idiopathic Pulmonary Fibrosis Market
Segmentations in the Report
By Indication
By Molecule Type
By Distribution Channel
By Region
Frequently Asked Questions
What is the expected market value of Idiopathic Pulmonary Fibrosis Market in 2029?
Global Idiopathic Pulmonary Fibrosis Market is expected to be valued at USD 10638.61 Million in 2029.
At what growth rate is Idiopathic Pulmonary Fibrosis Market expected to grow in the forecast period?
During 2024-2029, Idiopathic Pulmonary Fibrosis Market is expected to grow at CAGR of 12.61%.
Which Region dominates the Idiopathic Pulmonary Fibrosis Market?
Americas contributes the largest revenue share in the Idiopathic Pulmonary Fibrosis Market.
At what rate will Americas Idiopathic Pulmonary Fibrosis Market Grow?
During 2024-2029, Americas Idiopathic Pulmonary Fibrosis Market is expected to grow at a CAGR of 11.98%.
1. Market Background
1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology
2. Strategic Recommendations
2.1 Enhancing R&D operations for the development of novel treatments
2.2 Improving access to treatment
3. Global Idiopathic Pulmonary Fibrosis Market: Historic and Forecast
3.1 Impact Analysis of Macro Economic Factors on Idiopathic Pulmonary Fibrosis Market
3.2 Most bothersome IPF symptom
3.3 Idiopathic Pulmonary Fibrosis diagnosed prevalent cases
3.4 Competitive Landscape for IPF Drugs in Pipeline
3.5 Chronic Cough due to IPF
3.6 Idiopathic Pulmonary Fibrosis: Fact Sheet
3.7 Pathophysiology of Chronic Cough due to IPF
3.8 Comorbidities Associated with Chronic Cough in IPF
3.9 Global Idiopathic Pulmonary Fibrosis Market: Dashboard
3.10 Global Idiopathic Pulmonary Fibrosis Market: Market Value Assessment, 2018-2028 (USD Million)
3.11 Impact of COVID-19 on Global Idiopathic Pulmonary Fibrosis Market
3.12 Global Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type
3.12.1 Global Idiopathic Pulmonary Fibrosis Market, By Drug Type Type Overview
3.12.2 Global Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)
3.12.3 Global Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)
3.12.4 Global Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)
3.13 Global Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration
3.13.1 Global Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview
3.13.2 Global Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
3.13.3 Global Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)
3.13.4 Global Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
3.14 Global Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel
3.14.1 Global Idiopathic Pulmonary Fibrosis Market, By Distribution Channel Overview
3.14.2 Global Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies By Value, 2018H-2028F (USD Million & CAGR)
3.14.3 Global Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
3.14.4 Global Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2018H-2028F (USD Million & CAGR)
4. Global Idiopathic Pulmonary Fibrosis Market, Regional Analysis
4.1 Regional Coverage of the Study
5. Americas Idiopathic Pulmonary Fibrosis Market: Historic and Forecast (2018-2028)
5.1 Americas Idiopathic Pulmonary Fibrosis Market: Snapshot
5.2 Americas Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
5.3 Americas Idiopathic Pulmonary Fibrosis Market: Key Factors
5.4 Americas Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type
5.4.1 Americas Idiopathic Pulmonary Fibrosis Market, By Drug Type Overview
5.4.2 Americas Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)
5.4.3 Americas Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)
5.4.4 Americas Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)
5.5 Americas Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration
5.5.1 Americas Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview
5.5.2 Americas Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
5.5.3 Americas Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)
5.5.4 Americas Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
5.6 Americas Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel
5.6.1 Americas Idiopathic Pulmonary Fibrosis Market, By Distribution Channel Overview
5.6.2 Americas Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
5.6.3 Americas Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
5.6.4 Americas Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2018H-2028F (USD Million & CAGR)
5.7 Americas Idiopathic Pulmonary Fibrosis Market Segmentation: By Country
5.7.1 United States Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
5.7.1.1 United States Idiopathic Pulmonary Fibrosis Market, By Drug Type
5.7.1.2 United States Idiopathic Pulmonary Fibrosis Market, By Route of Administration
5.7.1.3 United States Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
5.7.2 Canada Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
5.7.2.1 Canada Idiopathic Pulmonary Fibrosis Market, By Drug Type
5.7.2.2 Canada Idiopathic Pulmonary Fibrosis Market, By Route of Administration
5.7.2.3 Canada Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
5.7.3 Rest of Americas Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
5.7.3.1 Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Drug Type
5.7.3.2 Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Route of Administration
5.7.3.3 Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Route of Administration
6. Europe Idiopathic Pulmonary Fibrosis Market: Historic and Forecast (2018-2028)
6.1 Europe Idiopathic Pulmonary Fibrosis Market: Snapshot
6.2 Europe Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
6.3 Europe Idiopathic Pulmonary Fibrosis Market: Key Factors
6.4 Europe Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type
6.4.1 Europe Idiopathic Pulmonary Fibrosis Market, By Drug Type Overview
6.4.2 Europe Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)
6.4.3 Europe Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)
6.4.4 Europe Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)
6.5 Europe Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration
6.5.1 Europe Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview
6.5.2 Europe Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
6.5.3 Europe Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)
6.5.4 Europe Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
6.6 Europe Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel
6.6.1 Europe Idiopathic Pulmonary Fibrosis Market, By Distribution Channel Overview
6.6.2 Europe Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
6.6.3 Europe Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
6.7 Europe Idiopathic Pulmonary Fibrosis Market Segmentation: By Country
6.7.1 France Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
6.7.1.1 France Idiopathic Pulmonary Fibrosis Market, By Drug Type
6.7.1.2 France Idiopathic Pulmonary Fibrosis Market, By Route of Administration
6.7.1.3 France Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
6.7.2 United Kingdom Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
6.7.2.1 United Kingdom Idiopathic Pulmonary Fibrosis Market, By Drug Type
6.7.2.2 United Kingdom Idiopathic Pulmonary Fibrosis Market, By Route of Administration
6.7.2.3 United Kingdom Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
6.7.3 Italy Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
6.7.3.1 Italy Idiopathic Pulmonary Fibrosis Market, By Drug Type
6.7.3.2 Italy Idiopathic Pulmonary Fibrosis Market, By Route of Administration
6.7.3.3 Italy Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
6.7.4 Spain Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
6.7.4.1 Spain Idiopathic Pulmonary Fibrosis Market, By Drug Type
6.7.4.2 Spain Idiopathic Pulmonary Fibrosis Market, By Route of Administration
6.7.4.3 Spain Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
6.7.5 Germany Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
6.7.5.1 Germany Idiopathic Pulmonary Fibrosis Market, By Drug Type
6.7.5.2 Germany Idiopathic Pulmonary Fibrosis Market, By Route of Administration
6.7.5.3 Germany Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
6.7.6 Rest of Europe Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
6.7.6.1 Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Drug Type
6.7.6.2 Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Route of Administration
6.7.6.3 Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
7. Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Historic and Forecast (2018-2028)
7.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Snapshot
7.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
7.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Key Factors
7.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type
7.4.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Drug Type Overview
7.4.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)
7.4.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)
7.4.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)
7.5 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration
7.5.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview
7.5.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
7.5.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)
7.5.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
7.6 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel
7.6.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Distribution Channel Overview
7.6.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
7.6.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
7.6.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2018H-2028F (USD Million & CAGR)
7.7 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Segmentation: By Country
7.7.1 China Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
7.7.1.1 China Idiopathic Pulmonary Fibrosis Market, By Drug Type
7.7.1.2 China Idiopathic Pulmonary Fibrosis Market, By Route of Administration
7.7.1.3 China Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
7.7.2 Japan Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
7.7.1.1 Japan Idiopathic Pulmonary Fibrosis Market, By Drug Type
7.7.1.2 Japan Idiopathic Pulmonary Fibrosis Market, By Route of Administration
7.7.1.3 Japan Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
7.7.3 South Korea Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
7.7.3.1 South Korea Idiopathic Pulmonary Fibrosis Market, By Drug Type
7.7.3.2 South Korea Idiopathic Pulmonary Fibrosis Market, By Route of Administration
7.7.3.3 South Korea Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
7.7.4 India Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
7.7.4.1 India Idiopathic Pulmonary Fibrosis Market, By Drug Type
7.7.4.2 India Idiopathic Pulmonary Fibrosis Market, By Route of Administration
7.7.4.3 India Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
7.7.5 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
7.7.5.1 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Drug Type
7.7.5.2 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Route of Administration
7.7.5.3 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
8. Middle-East & Africa Idiopathic Pulmonary Fibrosis Market: Historic and Forecast (2018-2028)
8.1 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market: Snapshot
8.2 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
8.3 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market: Key Factors
8.4 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type
8.4.1 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market, By Drug Type Overview
8.4.2 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)
8.4.3 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)
8.4.4 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)
8.5 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration
8.5.1 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview
8.5.2 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
8.5.3 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)
8.5.4 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
8.6 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel
8.6.1 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market, By Distribution Channel: Overview
8.6.2 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
8.6.3 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
8.6.4 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2018H-2028F (USD Million & CAGR)
9. Market Dynamics
9.1 Impact Assessment of Market Dynamics on the Global Idiopathic Pulmonary Fibrosis Market
9.2 Drivers
9.3 Restraints
9.4 Trends
10. Industry Ecosystem Analysis
10.1 Macro-Economic Factor Assessment
10.2 Porter’s Five Forces Model
11. Competitive Positioning
11.1 Companies’ Product Positioning
11.2 Market Position Matrix
11.3 Market Share Analysis of Idiopathic Pulmonary Fibrosis Market
11.4 Company Profiles
11.4.1 Boehringer Ingelheim
11.4.2 F. Hoffmann-La Roche AG
11.4.3 Cipla Ltd.
11.4.4 Shionogi & Co., Ltd.
11.4.5 Bristol-Myers Squibb Co.
11.4.6 United Therapeutics
11.4.7 FibroGen, Inc.
11.4.8 Pliant Therapeutics
11.4.9 Galecto Inc.
11.4.10 CSL Behring
List of Figures
Figure 1: Most bothersome IPF symptom
Figure 2: Global IPF diagnosed prevalent cases,2023 (Millions)
Figure 3: Global Idiopathic Pulmonary Fibrosis Market Size, By Value, 2019-2022 (USD Million)
Figure 4: Global Idiopathic Pulmonary Fibrosis Market Size, By Value, 2023-2029 (USD Million)
Figure 5: Global Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, 2022 (%)
Figure 6: Global Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2019H-2029F (USD Million & CAGR)
Figure 7: Global Idiopathic Pulmonary Fibrosis Market Absolute Opportunity, By Pirfenidone, 2019-2029 (USD Million)
Figure 8: Global Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2019H-2029F (USD Million & CAGR)
Figure 9: Global Idiopathic Pulmonary Fibrosis Market Absolute Opportunity, By Nintedanib, 2019-2029 (USD Million)
Figure 10: Global Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2019H-2029F (USD Million & CAGR)
Figure 11: Global Idiopathic Pulmonary Fibrosis Market Absolute Opportunity, By Other drugs, 2019-2029 (USD Million)
Figure 12: Global Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
Figure 13: Global Idiopathic Pulmonary Fibrosis Market Absolute Opportunity, By Oral, 2019-2029 (USD Million)
Figure 14: Global Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2019H-2029F (USD Million & CAGR)
Figure 15: Global Idiopathic Pulmonary Fibrosis Market Absolute Opportunity, By Parenteral, 2019-2029 (USD Million)
Figure 16: Global Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2019H-2029F (USD Million & CAGR)`
Figure 17: Global Idiopathic Pulmonary Fibrosis Market Absolute Opportunity, By Other ROA, 2019-2029 (USD Million)
Figure 18: Global Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 19: Global Idiopathic Pulmonary Fibrosis Market Absolute Opportunity, By Hospital Pharmacies, 2019-2029 (USD Million)
Figure 20: Global Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 21: Global Idiopathic Pulmonary Fibrosis Market Absolute Opportunity, By Retail Pharmacies, 2019-2029 (USD Million)
Figure 22: Global Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2019H-2029F (USD Million & CAGR)
Figure 23: Global Idiopathic Pulmonary Fibrosis Market Absolute Opportunity, By Online Channel, 2019-2029 (USD Million)
Figure 24: Americas Idiopathic Pulmonary Fibrosis Market Size, By Value, 2019H-2029F (USD Million)
Figure 25: Americas Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, 2022 (%)
Figure 26: Americas Idiopathic Pulmonary Fibrosis Market, By Pirfenidone, By Value, 2019H-2029F (USD Million & CAGR)
Figure 27: Americas Idiopathic Pulmonary Fibrosis Market, By Nintedanib, By Value, 2019H-2029F (USD Million & CAGR)
Figure 28: Americas Idiopathic Pulmonary Fibrosis Market, By Other drugs, By Value, 2019H-2029F (USD Million & CAGR)
Figure 29: Americas Idiopathic Pulmonary Fibrosis Market, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
Figure 30: Americas Idiopathic Pulmonary Fibrosis Market, By Parenteral, By Value, 2019H-2029F (USD Million & CAGR)
Figure 31: Americas Idiopathic Pulmonary Fibrosis Market, By Other ROA, By Value, 2019H-2029F (USD Million & CAGR)
Figure 32: Americas Idiopathic Pulmonary Fibrosis Market, By Hospital Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 33: Americas Idiopathic Pulmonary Fibrosis Market, By Retail Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 34: Americas Idiopathic Pulmonary Fibrosis Market, By Online Channel, By Value, 2019H-2029F (USD Million & CAGR)
Figure 35: United States Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 36: United States Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
Figure 37: United States Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
Figure 38: United States Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, By Value, 2022 (%)
Figure 39: United States Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
Figure 40: Canada Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 41: Canada Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
Figure 42: Canada Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
Figure 43: Canada Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
Figure 44: Canada Idiopathic Pulmonary Fibrosis Market Share, Distribution Channel, 2022 (%)
Figure 45: Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 46: Rest of Americas Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
Figure 47: Rest of Americas Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
Figure 48: Rest of Americas Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
Figure 49: Rest of Americas Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
Figure 50: Europe Idiopathic Pulmonary Fibrosis Market Size, By Value, 2019H-2029F (USD Million)
Figure 51: Europe Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, 2022 (%)
Figure 52: Europe Idiopathic Pulmonary Fibrosis Market, By Pirfenidone, By Value, 2019H-2029F (USD Million & CAGR)
Figure 53: Europe Idiopathic Pulmonary Fibrosis Market, By Nintedanib, By Value, 2019H-2029F (USD Million & CAGR)
Figure 54: Europe Idiopathic Pulmonary Fibrosis Market, By Other drugs, By Value, 2019H-2029F (USD Million & CAGR)
Figure 55: Europe Idiopathic Pulmonary Fibrosis Market, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
Figure 56: Europe Idiopathic Pulmonary Fibrosis Market, By Parenteral, By Value, 2019H-2029F (USD Million & CAGR)
Figure 57: Europe Idiopathic Pulmonary Fibrosis Market, By Other ROA, By Value, 2019H-2029F (USD Million & CAGR)
Figure 58: Europe Idiopathic Pulmonary Fibrosis Market, By Hospital Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 59: Europe Idiopathic Pulmonary Fibrosis Market, By Retail Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 60: Europe Idiopathic Pulmonary Fibrosis Market, By Online Channel, By Value, 2019H-2029F (USD Million & CAGR)
Figure 61: France Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 62: France Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
Figure 63: France Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
Figure 64: France Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
Figure 65: France Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
Figure 66: United Kingdom Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 67: United Kingdom Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
Figure 68: United Kingdom Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
Figure 69: United Kingdom Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
Figure 70: United Kingdom Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
Figure 71: Italy Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 72: Italy Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
Figure 73: Italy Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
Figure 74: Italy Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
Figure 75: Italy Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
Figure 76: Spain Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 77: Spain Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
Figure 78: Spain Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
Figure 79: Spain Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
Figure 80: Spain Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
Figure 81: Germany Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 82: Germany Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
Figure 83: Germany Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
Figure 84: Germany Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
Figure 85: Germany Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
Figure 86: Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 87: Rest of Europe Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
Figure 88: Rest of Europe Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
Figure 89: Rest of Europe Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
Figure 90: Rest of Europe Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
Figure 91: Asia Pacific Idiopathic Pulmonary Fibrosis Market Size, By Value, 2019H-2029F (USD Million)
Figure 92: Asia Pacific Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, 2022 (%)
Figure 93: Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Pirfenidone, By Value, 2019H-2029F (USD Million & CAGR)
Figure 94: Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Nintedanib, By Value, 2019H-2029F (USD Million & CAGR)
Figure 95: Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Other drugs, By Value, 2019H-2029F (USD Million & CAGR)
Figure 96: Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
Figure 97: Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Parenteral, By Value, 2019H-2029F (USD Million & CAGR)
Figure 98: Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Other ROA, By Value, 2019H-2029F (USD Million & CAGR)
Figure 99: Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Hospital Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 100: Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Retail Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 101: Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Online Channel, By Value, 2019H-2029F (USD Million & CAGR)
Figure 102: China Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 103: China Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
Figure 104: China Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
Figure 105: China Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
Figure 106: China Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
Figure 107: Japan Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 108: Japan Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
Figure 109: Japan Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
Figure 110: Japan Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
Figure 111: Japan Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
Figure 112: South Korea Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 113: South Korea Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
Figure 114: South Korea Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
Figure 115: South Korea Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
Figure 116: South Korea Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
Figure 117: India Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 118: India Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
Figure 119: India Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
Figure 120: India Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
Figure 121: India Idiopathic Pulmonary Fibrosis Market Share, Distribution Channel, 2022 (%)
Figure 122: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Value, 2019-2029 (USD Million & CAGR)
Figure 123: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market Value, By Drug Type, 2022 (USD Million)
Figure 124: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, By Value, 2022 (%)
Figure 125: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market Share, By Route of Administration, 2022 (%)
Figure 126: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market Share, By Distribution Channel, 2022 (%)
Figure 127: Middle East and Africa Idiopathic Pulmonary Fibrosis Market Size, By Value, 2019H-2029F (USD Million)
Figure 128: Middle East and Africa Idiopathic Pulmonary Fibrosis Market Share, By Drug Type, 2022 (%)
Figure 129: Middle East and Africa Idiopathic Pulmonary Fibrosis Market, By Pirfenidone, By Value, 2019H-2029F (USD Million & CAGR)
Figure 130 Middle East and Africa Idiopathic Pulmonary Fibrosis Market, By Nintedanib, By Value, 2019H-2029F (USD Million & CAGR)
Figure 131 Middle East and Africa Idiopathic Pulmonary Fibrosis Market, By Other drugs, By Value, 2019H-2029F (USD Million & CAGR)
Figure 132: Middle East and Africa Idiopathic Pulmonary Fibrosis Market, By Oral, By Value, 2019H-2029F (USD Million & CAGR)
Figure 133: Middle East and Africa Idiopathic Pulmonary Fibrosis Market, By Parenteral, By Value, 2019H-2029F (USD Million & CAGR)
Figure 134: Middle East and Africa Idiopathic Pulmonary Fibrosis Market, By Other ROA, By Value, 2019H-2029F (USD Million & CAGR)
Figure 135: Middle East and Africa Idiopathic Pulmonary Fibrosis Market, By Hospital Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 136: Middle East and Africa Idiopathic Pulmonary Fibrosis Market, By Retail Pharmacies, By Value, 2019H-2029F (USD Million & CAGR)
Figure 137: Middle East and Africa Idiopathic Pulmonary Fibrosis Market, By Online Channel, By Value, 2019H-2029F (USD Million & CAGR)
Figure 138: Global Impact of Drivers and Restraints
Figure 139: Market Share of Prominent Companies of Idiopathic Pulmonary Fibrosis Market, 2022 (%)
Figure 140: Roche Revenues, 2020-2022 (USD Million)
Figure 141: Roche Revenue , By Business Segment, 2022 (%)
Figure 142: Cipla Revenues, 2020-2022 (USD Million)
Figure 143: Cipla Revenues, By Geographic Segments, 2022 (%)
Figure 144: Cipla Revenue , By Business Segments, 2022 (%)
Figure 145: Shionogi & Co., Revenues, 2020-2022 (USD Million)
Figure 146: Shionogi & Co., Revenues, By Geographic Segments, 2022 (%)
Figure 147: Shionogi & Co., Revenue , By Therapeutic Area, 2022 (%)
Figure 148: Bristol-Myers Squibb Revenues, 2020-2022 (USD Million)
Figure 149: Bristol-Myers Squibb Revenues, By Geographic Segments, 2022 (%)
Figure 150: United Therapeutics Revenues, 2020-2022 (USD Million)
Figure 151: United Therapeutics Revenues, By Geographic Segments, 2022 (%)
Figure 152: United Therapeutics Revenues, By commercial products, 2022 (%)
Figure 153: Pliant Therapeutics Revenues, 2020-2022 (USD Thousand)
Figure 154: CSL Behring Revenues, 2020-2022 (USD Million)
Figure 155: CSL Behring Revenues, By Geographic Segments, 2022 (%)
Figure 156: CSL Behring Revenue , By Therapeutic Area, 2022 (%)
List of Tables
Table A1: Global Impact of Macro Economic Factors, By Region
Table A2: Competitive landscape for IPF drugs in Pipeline
Table A3: Unmet need of Patients with Chronic Cough
Table A4: Comorbid conditions associated with chronic cough in patients with IPF.
Table A5: United States Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A6: United States Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A7: United States Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A8: United States Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A9: United States Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A10: United States Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A11: Canada Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A12: Canada Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A13: Canada Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A14: Canada Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A15: Canada Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A16: Canada Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A17: Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A18: Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A19: Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A20: Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A21: Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A22: Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A23: France Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A24: France Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A25: France Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A26: France Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A27: France Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A28: France Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A29: United Kingdom Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million
Table A30: United Kingdom Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A31: United Kingdom Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A32: United Kingdom Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A33: United Kingdom Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A34: United Kingdom Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A35: Italy Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A36: Italy Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A37: Italy Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A38: Italy Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A39: Italy Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A40: Italy Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A41: Spain Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A42: Spain Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A43: Spain Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A44: Spain Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A45: Spain Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A46: Spain Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A47: Germany Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A48: Germany Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A49: Germany Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A50: Germany Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A51: Germany Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A52: Germany Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A53: Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A54: Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A55: Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A56: Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A57: Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A58: Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A59: China Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A60: China Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A61: China Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A62: China Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A63: China Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A64: China Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A65: Japan Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A66: Japan Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A67: Japan Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A68: Japan Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A69: Japan Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A70: Japan Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A71: South Korea Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A72: South Korea Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A73: South Korea Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A74: South Korea Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A75: South Korea Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A76: South Korea Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A77: India Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A78: India Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A79: India Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A80: India Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A81: India Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A82: India Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A83: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2019-2022 (USD Million)
Table A84: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Drug Type, By Value, 2023-2029 (USD Million)
Table A85: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2019-2022 (USD Million)
Table A86: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Route of Administration, By Value, 2023-2029 (USD Million)
Table A87: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2019-2022 (USD Million)
Table A88: Rest of Asia Pacific Idiopathic Pulmonary Fibrosis Market, By Distribution Channel, By Value, 2023-2029 (USD Million)
Table A89: Roche Key Financials, 2020-2022
Table A90: Cipla Key Financials, 2020-2022
Table A91: Shionogi & Co., Key Financials, 2020-2022
Table A92: Bristol-Myers Squibb Key Financials, 2020-2022
Table A93: United Therapeutics Key Financials, 2020-2022
Table A94: Pliant Therapeutics Key Financials, 2020-2022
Table A95: Galecto Key Financials, 2020-2022
Table A96: CSL Behring Key Financials, 2020-2022
.jpg)
Global Medical Device Regulatory Affairs Market (2024 Edition): Analysis By Type ...
Read More.jpg)
Global Infectious Disease In vitro Diagnostics Market (2024 Edition): Analysis B ...
Read More
Global Medical Tourism Market (2024 Edition): Analysis By Service Provider (Publ ...
Read More.jpg)
Global Oxygen Cylinders and Concentrators Market (2024 Edition): Analysis By Pro ...
Read More.jpg)
Global Fertility Services Market (2024 Edition): Analysis By Gender (Male, Femal ...
Read More.jpg)
Global Irritable Bowel Disease Market (2024 Edition): Analysis By Drug Class (Co ...
Read More.jpg)
Global Immune Thrombocytopenia Drug Market (2024 Edition): Analysis By Treatment ...
Read More.jpg)
Global IgG Mediated Autoimmune Diseases Biologic Drugs Market (2024 Edition): An ...
Read MoreNo matter the hour, we’re here to help.
Contact us now!.jpg){kind=logo}
Azoth Analytics (ISO 9001:2015) is a business research and analytics company that creates in-depth research reports and provides customized research solutions and consulting services.
© 2024 Azoth Analytics | All rights reserved